Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 47 of 47 publications.

Moss E, Burrell A, Lee J, Reichenbach D, Mitchell S, Yan S, Thiruvillakkat K. Economic and humanistic burden in kidney transplant rejection: a literature review. Expert Rev Pharmacoecon Outcomes Res. 2024 Mar;24(3):343-52. doi: 10.1080/14737167.2024.2305140

Desai RJ, Wang SV, Sreedhara SK, Zabotka L, Khosrow-Khavar F, Nelson JC, Shi X, Toh S, Wyss R, Patorno E, Dutcher S, Li J, Lee H, Ball R, Dal Pan G, Segal JB, Suissa S, Rothman KJ, Greenland S, Hernan MA, Heagerty PJ, Schneeweiss S. Process guide for inferential studies using healthcare data from routine clinical practice to evaluate causal effects of drugs (PRINCIPLED): considerations from the FDA Sentinel Innovation Center. BMJ. 2024 Feb 12;384:e076460. doi: 10.1136/bmj-2023-076460

Fernandez MM, Bell T, Tumminello B, Khan S, Zhou S, Oton AB. Disease and economic burden of surgery in desmoid tumors: a review. Expert Rev Pharmacoecon Outcomes Res. 2023 Jul;23(6):607-18. doi: 10.1080/14737167.2023.2203915

Skajaa N, Adelborg K, Horvath-Puho E, Rothman KJ, Henderson VW, Thygesen LC, Sorensen HT. Labour market participation and retirement after stroke in Denmark: registry based cohort study. BMJ. 2023 Jan 3;380:e072308. doi: 10.1136/bmj-2022-072308

Poulos C, Xu Y, Botha W, Leach C, Wrobleski KK, Gordon K, Missmer SA, Estes SJ. A discrete-choice experiment study of physicians' prioritization of attributes of medical treatments for endometriosis-associated pain. Expert Rev Pharmacoecon Outcomes Res. 2023 Jan;23(1):111-21. doi: 10.1080/14737167.2023.2152006

Herring W, Ciarametaro M, Mauskopf J, Wamble D, Sils B, Dubois R. What might have happened: the impact of interrupting entry of innovative drugs on disease outcomes in the United States. Expert Rev Pharmacoecon Outcomes Res. 2022 Jun;22(4):529-41. doi: 10.1080/14737167.2022.2035219

Flem E, Graham J, Yi Z, Wisloff T, Johnson KD. Cost and health impact analysis of herpes zoster vaccination in Norway. Expert Rev Pharmacoecon Outcomes Res. 2022 Mar;22(2):315-26. doi: 10.1080/14737167.2021.1973893

Ackley SF, Zimmerman SC, Brenowitz WD, Tchetgen Tchetgen EJ, Gold AL, Manly JJ, Mayeda ER, Filshtein TJ, Power MC, Elahi FM, Brickman AM, Glymour MM. Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis. BMJ. 2021 Feb 25;372:n156. doi: 10.1136/bmj.n156

Goyal RK, Cuyun Carter G, Nagar SP, Nash Smyth E, Price GL, Parikh RC, Huang YJ, Li L, Davis KL, Kaye JA. Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2- metastatic breast cancer in the United States. Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):699-710. doi: 10.1080/14737167.2020.1804871

Yland JJ, Bresnick KA, Hatch EE, Wesselink AK, Mikkelsen EM, Rothman KJ, Sorensen HT, Huybrechts KF, Wise LA. Pregravid contraceptive use and fecundability: prospective cohort study. BMJ. 2020 Nov 11;371:m3966. doi: 10.1136/bmj.m3966

Poulos C, Soliman AM, Tekin S, Agarwal SK. Patient preferences for elagolix and leuprolide for treating endometriosis-related pain in the United States. Expert Rev Pharmacoecon Outcomes Res. 2020 Nov 3;1-9. doi: 10.1080/14737167.2021.1832468

Himmler S, Mueller M, Sherif B, Ostwald D. A case study applying a novel approach to estimate the social impact of a medical innovation - the use of secukinumab for psoriatic arthritis in Germany. Expert Rev Pharmacoecon Outcomes Res. 2019 Jul 29. doi: 10.1080/14737167.2019.1644169

Pajouheshnia R, Groenwold RHH, Peelen LM, Reitsma JB, Moons KGM. When and how to use data from randomised trials to develop or validate prognostic models. BMJ. 2019 May 29;356:I2154. doi: 10.1136/bmj.l2154

Obel N, Dessau RB, Krogfelt KA, Bodilsen J, Andersen NS, Moller JK, Roed C, Omland LH, Christiansen CB, Ellermann-Eriksen S, Bangsborg JM, Hansen K, Benfield TL, Rothman KJ, Sorensen HT, Andersen NS, Lebech AM. Long term survival, health, social functioning, and education in patients with European Lyme neuroborreliosis: nationwide population based cohort study. BMJ. 2018 May 30;361:k1998. doi: 10.1136/bmj.k1998

Basu A, Dalal A, Canonica GW, Forshag M, Yancey SW, Nagar S, Bell CF. Economic analysis of the Phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Rev Pharmacoecon Outcomes Res. 2017 Apr;17(2):121-31. doi: 10.1080/14737167.2017.1298444

Mikkelsen EM, Riis AH, Wise LA, Hatch EE, Rothman KJ, Cueto HT, Sørensen HT. Alcohol consumption and fecundability: prospective Danish cohort study. BMJ. 2016 Aug 31;354:i4262. doi: 10.1136/bmj.i4262

Clark M, DiBenedetti D, Perez V. Cognitive dysfunction and work productivity in major depressive disorder. Expert Rev Pharmacoecon Outcomes Res. 2016 Jun 8. doi: 10.1080/14737167.2016.1195688

Sawant RV, Goyal RK, Rajan SS, Essien EJ, Patel HK, Sansgiry SS. Factors associated with intention to engage in self-protective behavior: the case of over-the-counter acetaminophen products. Res Social Adm Pharm. 2016 Mar;12(2):327-35. doi: 10.1016/j.sapharm.2015.06.005

Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, Septe M, Elewski BE, Gottlieb AB, Zhao Y, Herrera V, Mordin M, Odom D, Papavassilis C, Nyirady J, Lebwohl M. Secukinumab provides clearer skin and better control on patient-reported psoriasis symptoms of itching, pain, and scaling than placebo and etanercept. J Psoriasis and Psoriatic Arthritis. 2016;1(4):167-75.

Brennan VK, Mauskopf JA, Colosia AD, Copley-Merriman K, Hass B, Palencia R. Utility estimates for patients with type 2 diabetes mellitus after experiencing a myocardial infarction or stroke: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2015 Feb;15(1):111-23.

Warttig S, Ward S, Rogers G, Guideline Development Group. Diagnosis and management of gallstone disease: summary of NICE guidance. BMJ. 2014 Oct 30;349:g6241. doi: 10.1136/bmj.g6241

Chen WH, McLeod L, Nelson LM, Williams VS, Fehnel SE. Quantitative challenges facing patient-centered outcomes research. Expert Rev Pharmacoecon Outcomes Res. 2014 Jun 14;14(3):379-86.

Von Schéele B, Mauskopf J, Brodtkorb TH, Ainsworth C, Berardo CG, Patel A. Relationship between modeling technique and reported outcomes: case studies in models for the treatment of schizophrenia. Expert Rev Pharmacoecon Outcomes Res. 2014 Apr;14(2):235-57. doi: 10.1586/14737167.2014.891443

Fehnel S, DeMuro C, McLeod L, Coon C, Gnanasakthy A. FDA patient-reported outcome guidance: great expectations and unintended consequences. Expert Rev Pharmacoecon Outcomes Res. 2013;13(4):441-6.

Mauskopf J, Talbird S, Standaert B. Categorization of methods used in cost-effectiveness analyses of vaccination programs based on outcomes from dynamic transmission models. Expert Rev Pharmacoecon Outcomes Res. 2012 Jun 1;12(3):357-71.

DeMuro CJ, Lewis SA, DiBenedetti DB, Price MA, Fehnel SE. Successful implementation of cognitive interviews in special populations. Expert Rev Pharmacoecon Outcomes Res. 2012 Apr 1;12(2):181-7.

McLeod LD, Coon CD, Martin SA, Fehnel SE, Hays RD. Interpreting patient-reported outcome results: uS FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res. 2011 Apr 1;11(2):163-9.

Wolowacz SE. Pharmacoeconomics of dabigatran etexilate for prevention of thromboembolism after joint replacement surgery. Expert Rev Pharmacoecon Outcomes Res. 2011 Feb 1;11(1):9-25.

Nagar S, Mehta S, Bhatara V, Aparasu R. Health care consequences of black-box warnings for antidepressants in the United States and Canada. Res Social Adm Pharm. 2010 Mar;6(1):78-84.

Martinez C, Assimes TL, Mines D, Dell'aniello S, Suissa S. Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death: a nested case-control study. BMJ. 2010 Feb 5;340:c249. doi: 10.1136/bmj.c249

Starke JR, Mucci L, Rothman KJ, Adami HO. Screening for prostate cancer remains controversial. BMJ. 2009 Sep 24;339(7724):b3601.

Rubino A, Roskell NS, Tennis P, Mines D, Weich S, Andrews E. Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. BMJ. 2007 Feb 3;334(7587):242-5.

Rothman KJ, Evans S. More on JAMA's policy on industry sponsored studies. BMJ. 2006 Feb 25;332(7539):489.

Mauskopf JA, Earnshaw SR, Mullins C. Budget impact analysis: review of the state of the art. Expert Rev Pharmacoecon Outcomes Res. 2005 Feb;5(1):65-79.

Rothman KJ, Evans S. Extra scrutiny for industry funded trials. BMJ. 2005 Jan 1;331(7529):1350-1.

Ryan M, Watson V, Amaya-Amaya M. Methodological issues in the monetary valuation of benefits in healthcare. Expert Rev Pharmacoecon Outcomes Res. 2003 Dec;3(6):717-27. doi: 10.1586/14737167.3.6.717

Duff SB, Mordin MM. Strategies for assessing health economic and quality-of-life outcomes in multiple sclerosis. Expert Rev Pharmacoecon Outcomes Res. 2002 Dec;2(6):577-87.

Sorensen HT, Pedersen L, Nogard L, Fonager K, Rothman KJ. Does month of birth affect risk of Crohn's disease in childhood and adolescence? BMJ. 2001 Jan 1;323(7318):907.

Rothman KJ, Michels KB. Declaration of Helsinki should be strengthened. BMJ. 2000 Aug 12;321(7258):442-5.

Sorensen HT, Rothman KJ, Gillman MW, Steffensen FH, Fischer P, Sabroe S. Historical cohort study of in utero exposure to uterotonic drugs and cognitive function in young adult life. BMJ. 1999 Feb;318:433. doi: 10.1136/bmj.318.7181.433

Sorensen HT, Sabroe S, Rothman KJ, Gillman M, Fischer P, Sorensen TIA. Relation between weight and length at birth and body mass index in young adulthood: cohort study. BMJ. 1997 Nov 1;315(7116):1137.

Sorensen HT, Sabroe S, Olsen J, Rothman KJ, Gillman MW, Fischer P. Birth weight and cognitive function in young adult life: historical cohort study. BMJ. 1997 Aug 16;315(7105):401-3.

Perez GS, Garcia Rodriguez LA, Castellsague J, Duque OA. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ. 1997 Mar 15;314(7083):796-800.

Henry D, Lim LL, Garcia Rodriguez LA, Perez GS, Carson JL, Griffin M, Savage R, Logan R, Moride Y, Hawkey C, Hill S, Fries JT. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ. 1996 Jun 22;312(7046):1563-6.

Rothman KJ. Placebo mania. BMJ. 1996 Jan 1;313(7048):3-4.

Williams VSL, Wakeford ME. The predictive validity of the National Teacher Examinations for performance in teacher education programs. Educ Psychol Meas. 1993;53(2):533-9. doi: 10.1177/0013164493053002023

Garcia Rodriguez LA, Perez GS, Walker AM, Lueck L. The role of non-steroidal anti-inflammatory drugs in acute liver injury. BMJ. 1992 Oct 10;305(6858):865-86.